Trials Near Add Your Location
Accepting patients
CARTITUDE-10
A Phase 2 Multicohort Trial to Further Characterize the Efficacy and Safety of Ciltacabtagene Autoleucel
- CAR T Cell
- BCMA
- Phase 2
Accepting patients
Talisman
A Phase 2, Open-label, Randomized Study to Evaluate Prophylactic Interventions on Talquetamab-related Oral Toxicity
- Bispecific Antibody
- GPRC5D
- Randomization
- Phase 2
Accepting patients
MagnetisMM-32
Phase 3 Clinical Trial Comparing the Safety and Effectiveness of Elranatamab Versus Commonly Used Combination Regimens in Participants with Relapsed/Refractory Multiple Myeloma
- Bispecific Antibody
- BCMA
- Randomization
- Phase 3
Accepting patients
QUINTESSENTIAL-2
Phase 3 Clinical Trial Comparing the Safety and Efficacy of BMS-986393 to Standard of Care Regimens in Patients with Relapsed/Refractory Multiple Myeloma
- CAR T Cell
- GPRC5D
- Randomization
- Phase 3
Accepting patients
QUINTESSENTIAL
Phase 2 Study of BMS-986393, a GPRC5D-directed CART-Cell Therapy, in Participants with Relapsed or Refractory Multiple Myeloma
- CAR T Cell
- GPRC5D
- Phase 2
Accepting patients
EXCALIBER - Maintenance
Phase 3 Clinical Trial Comparing Iberdomide VS Lenalidomide as Maintenance Therapy Following Autologous Stem Cell Transplant in Participants with Newly Diagnosed Multiple Myeloma
- CELMoD
- Post-Autologous Stem Cell Transplant
- Randomization
- Phase 3
Accepting patients
DREAMM-10
Phase 3 Clinical Trial Comparing the Safety and Efficacy of Belantamab Mafodotin, Lenalidomide and Dexamethasone Versus Daratumumab, Lenalidomide and Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma who are Ineligible for Autologous Stem Cell Transplant
- Antibody Drug Conjugate (ADC)
- BCMA
- Phase 3
Accepting patients
inMMyCAR
A Phase 1 Study to Evaluate the Safety of KLN-1010, a Novel, In Vivo Gene Therapy to Generate Anti-B Cell Maturation Antigen (Anti-BCMA) Chimeric Antigen Receptor-T Cells (CAR-T) in Patients With Relapsed and Refractory Multiple Myeloma
- CAR T Cell
- BCMA
- Phase 1
- Has results
Accepting patients
MagnetisMM-6
Phase 3 Clinical Trial Comparing the Safety and Effectiveness of Elranatamab combined with Daratumumab and Lenalidomide Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients Who Are Ineligible for Transplant
- Phase 3
Accepting patients
Talquetamab Consolidation After BCMA CAR-T
Talquetamab Consolidation After BCMA CART Cell Therapy for Relapsed or Refractory Multiple Myeloma
- Bispecific Antibody
- GPRC5D
- Post-CAR T
- Phase 2
44 hidden based on your filters.Show All